Neonatal Hyperparathyroidism and Pamidronate Therapy in an Extremely Premature Infant-Reference-Cited by-同舟云学术

Neonatal Hyperparathyroidism and Pamidronate Therapy in an Extremely Premature Infant

Published:2007-11-01 Issue:5 Volume:120 Page:e1350-e1354
ISSN:0031-4005
Container-title:Pediatrics
language:en
Short-container-title:

Author:

Fox Lisa¹,Sadowsky Joel¹,Pringle Kevin P.¹²³,Kidd Alexa⁴,Murdoch Jean⁵,Cole David E.C.⁶,Wiltshire Esko¹⁴⁷

Affiliation:

1. Departments of Paediatrics and Child Health

2. Surgery

3. Obstetrics and Gynaecology

4. Central Regional Genetics Service, Wellington Hospital, Capital and Coast District Health Board, Wellington, New Zealand; Departments of

5. Radiology

6. Departments of Laboratory Medicine and Pathobiology, Medicine, and Pediatrics, University of Toronto, Toronto, Ontario, Canada

7. Paediatrics and Child Health, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand

Abstract

We describe the use of pamidronate to control marked hypercalcemia in an extremely premature infant with neonatal hyperparathyroidism that resulted from an inactivating mutation (R220W) of the calcium-sensing receptor. Despite improvement in bone mineralization and subsequent parathyroidectomy with normalization of the serum calcium level, the combination of chronic lung disease, osteomalacia, and poor thoracic cage growth ultimately proved fatal. Pamidronate therapy seems to be safe in the short-term and effective in helping control hypercalcemia even in the very premature infant, allowing for planned surgical intervention when it becomes feasible.

Publisher

American Academy of Pediatrics (AAP)

Subject

Pediatrics, Perinatology and Child Health

Link

https://publications.aap.org/pediatrics/article-pdf/120/5/e1350/1031633/zpe011070e1350.pdf

Reference29 articles.

1. Rhone DP. Primary neonatal hyperparathyroidism: report of a case and review of the literature. Am J Clin Pathol. 1975;64:488–499

2. Waller S, Kurzawinski T, Spitz L, et al. Neonatal severe hyperparathyroidism: genotype/phenotype correlation and the use of pamidronate as rescue therapy. Eur J Pediatr. 2004;163:589–594

3. Marx SJ, Attie MF, Spiegel AM, et al. An association between neonatal severe primary hyperparathyroidism and familial hypocalciuric hypercalcemia in three kindreds. N Engl J Med. 1982;306:257–264

4. Cole DEC, Janicic N, Salisbury SR, Hendy GN. Neonatal severe hyperparathyroidism, secondary hyperparathyroidism, and familial hypocalciuric hypercalcemia: multiple different phenotypes associated with an inactivating Alu insertion mutation of the calcium-sensing receptor gene [published correction appears in Am J Med Genet. 1997;72:251–252]. Am J Med Genet. 1997;71:202–210

5. Harris S, D'Ercole A. Neonatal hyperparathyroidism: the natural course in the absence of surgical intervention. Pediatrics. 1989;83:53–56

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Invited Mini Review Metabolic Bone Disease of Prematurity: Overview and Practice Recommendations;Hormone Research in Paediatrics;2024-01-11

2. Surgical management of neonatal severe hyperparathyroidism;Annals of Saudi Medicine;2023-11

3. Neonatal severe hyperparathyroidism: a case report;Journal of the Pakistan Medical Association;2022-06-07

4. Disorders of the Calcium Sensing Signaling Pathway: From Familial Hypocalciuric Hypercalcemia (FHH) to Life Threatening Conditions in Infancy;Journal of Clinical Medicine;2022-05-05

5. Case Report: Severe Neonatal Course in Paternally Derived Familial Hypocalciuric Hypercalcemia;Frontiers in Endocrinology;2021-10-01